JAK2

The JAK2 gene encodes a critical enzyme involved in transmitting signals that regulate blood cell growth, survival, and development through the JAK-STAT pathway. Mutations in JAK2, particularly V617F, play a role in diagnosing, prognosis, and managing myeloproliferative neoplasms and other related hematologic conditions.

What is JAK2 (Janus Kinase 2)?

The JAK2 gene (Janus Kinase 2), located on chromosome 9p24.1, provides instructions for making a protein called JAK2, a type of enzyme known as a non-receptor tyrosine kinase. 

JAK2 plays a significant role in sending signals from outside the cell to the inside using the JAK-STAT pathway. These signals help control the growth, survival, and development of blood cells, especially those made by hematopoietic stem cells in the bone marrow. 

JAK2 is critical for maintaining normal blood production, supporting immune system function, and regulating healthy cell growth.

JAK2: A Tyrosine Kinase Involved in Cytokine Signaling

The JAK2 protein works closely with certain cell surface receptors that bind cytokines and growth factors. It connects with type I and type II cytokine receptors, including the erythropoietin receptor (EPOR), thrombopoietin receptor (MPL), growth hormone receptor (GHR), and several interleukin receptors. 

When a cytokine binds to its receptor, JAK2 becomes activated through autophosphorylation (adding a phosphate group to itself). Once active, JAK2 phosphorylates STAT proteins, which then move into the cell nucleus to turn specific genes on or off, controlling blood cell production, immune responses, and cell survival. 

JAK2 also plays a nuclear role by modifying histone H3 proteins at tyrosine 41, influencing how DNA is packaged and genes are expressed.

When is JAK2 Testing Relevant?

Testing for JAK2 mutations is often one of the first steps when doctors suspect a patient has a myeloproliferative neoplasm (MPN), a type of blood cancer in which the bone marrow makes too many blood cells.

The most common mutation, called V617F, is found in about 96% of patients with polycythemia vera (PV) and about 50–60% of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF). This mutation causes JAK2 to stay constantly active, leading to uncontrolled growth of blood cells.

In polycythemia vera, the JAK2 mutation causes the body to make too many red blood cells, which thickens the blood, increases the risk of blood clots, and limits oxygen delivery to tissues. 

In essential thrombocythemia, the mutation leads to too many platelets, raising the risk of both clotting and bleeding problems. 

In primary myelofibrosis, JAK2 mutations stimulate abnormal megakaryocytes (large platelet-forming cells) that release fibrotic factors, leading to scarring of the bone marrow, anemia, and enlarged spleen.

JAK2 mutations, especially V617F, have been found less commonly in acute myeloid leukemia (AML) and in Budd-Chiari syndrome (a blood clot in the liver’s veins).

Therefore, JAK2 testing is recommended for patients with unexplained high red blood cell counts (erythrocytosis), high platelet counts (thrombocytosis), marrow fibrosis, unusual blood clots, or suspected myeloproliferative disorders.

JAK2 Genetic Testing: Test Procedure and Interpretation

Testing for JAK2 is performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.

Testing Procedure and Preparation

Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types. 

A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.

Normal Reference Ranges

Normal reference ranges for JAK2 genetic testing are considered to be without mutations that can alter the activity of the JAK2 proteins.

What Do Specific JAK2 Mutations Mean?

Finding a JAK2 mutation strongly supports the diagnosis of an MPN. The V617F mutation is the most common and explains most cases of PV and a large share of ET and PMF. 

Exon 12 mutations are less common but are important in PV cases where the V617F mutation is absent. These patients usually have isolated red blood cell overproduction and low levels of erythropoietin.

The presence of a JAK2 mutation also has prognostic meaning. A higher mutant allele burden—meaning a greater proportion of cells with the mutation—can suggest more aggressive disease, greater risks of fibrosis, thrombosis, and faster progression. 

Some patients develop homozygosity for the mutation (both gene copies affected), which is linked to longer disease duration and worse outcomes.

JAK2 mutations are not only useful for diagnosis; they are also targets for therapy. JAK inhibitors (like ruxolitinib) are now commonly used to treat JAK2-positive MPNs. They help relieve symptoms, shrink enlarged spleens, and improve patients’ quality of life. 

Research continues on new ways to target JAK2 and related pathways like Lnk (SH2B3), which helps regulate JAK2 activity.

What Does the Absence of JAK2 Mutations Mean?

If a JAK2 mutation test is negative, it does not completely rule out an MPN. Other mutations, particularly in the CALR or MPL genes, can also cause these disorders. 

If doctors still suspect an MPN after a negative JAK2 test, further genetic testing should be done to look for other mutations. 

Full mutation profiling is important for making the right diagnosis and choosing the best treatment approach, as the type of mutation can affect how the disease behaves and responds to therapy.

Key Clinical Takeaways

The JAK2 gene produces a key enzyme that helps blood cells grow and mature through cytokine receptor signaling. The V617F mutation is a major marker found in most cases of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. 

Testing for JAK2 mutations is essential in diagnosing suspected BCR–ABL1–negative myeloproliferative neoplasms. 

Finding a JAK2 mutation confirms clonal blood cell growth and helps guide both prognosis and treatment, including the use of JAK2 inhibitors. However, a negative JAK2 test means other genetic causes, like CALR or MPL mutations, should be considered. 

Recognizing the presence and burden of JAK2 mutations is key to understanding disease severity, planning early intervention, and improving patient outcomes.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.